Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,387 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02452294 | Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)(BUMPER) | unknown | Phase 2 | 22 | University Hospital TuebingenOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00413192 | E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 128 | Eisai Inc.INDUSTRY | 5 | Apr 26, 2017 |
| clinicaltrials |
| NCT01493843 | Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | completed | Phase 2 | 501 | Genentech, Inc.INDUSTRY | 16 | Apr 25, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT02973191 | A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia(ORBIT) | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 7 | Apr 10, 2017 | clinicaltrials |
| NCT01110954 | Fluorescence-guided Resection in Breast Cancer | terminated | Phase 2 | 8 | photonamic GmbH & Co. KGINDUSTRY | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00332969 | Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma | completed | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00079105 | A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years | completed | Phase 2 | 175 | Newcastle-upon-Tyne Hospitals NHS TrustOTHER | 2 | Mar 30, 2017 | clinicaltrials |
| NCT02008539 | Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101(TREAT-ME 1) | terminated | Phase 1 / Phase 2 | 13 | Apceth GmbH & Co. KGINDUSTRY | 1 | Mar 27, 2017 | clinicaltrials |
| NCT00102726 | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy | completed | Phase 2 | 183 | GlaxoSmithKlineINDUSTRY | 19 | Mar 23, 2017 | clinicaltrials |
| NCT01204125 | Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients(SOLTI NEOPARP) | completed | Phase 2 | 141 | SanofiINDUSTRY | 3 | Mar 22, 2017 | clinicaltrials |
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | completed | Phase 2 | 365 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 20, 2017 | clinicaltrials |
| NCT01289821 | First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib | completed | Phase 2 | 54 | BayerINDUSTRY | 7 | Mar 15, 2017 | clinicaltrials |
| NCT01316263 | A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors | terminated | Phase 2 | 21 | Eli Lilly and CompanyINDUSTRY | 6 | Mar 9, 2017 | clinicaltrials |
| NCT01572727 | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation(BELLE-4) | completed | Phase 2 / Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 22 | Mar 9, 2017 | clinicaltrials |
| NCT01457846 | Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer(SHINE) | terminated | Phase 2 | 960 | AstraZenecaINDUSTRY | 16 | Mar 7, 2017 | clinicaltrials |
| NCT01209286 | Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 36 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01401166 | Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer(PrefHER) | completed | Phase 2 | 488 | Hoffmann-La RocheINDUSTRY | 12 | Mar 6, 2017 | clinicaltrials |
| NCT00874107 | Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 90 | HiberCell, Inc.INDUSTRY | 2 | Mar 3, 2017 | clinicaltrials |
| NCT00413036 | A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 2 | 217 | CelgeneINDUSTRY | 7 | Mar 1, 2017 | clinicaltrials |
| NCT00523380 | Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer | completed | Phase 2 | 10 | Novo Nordisk A/SINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT00601861 | Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer | terminated | Phase 2 | 1 | Novo Nordisk A/SINDUSTRY | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00617253 | Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients | completed | Phase 2 | 9 | Novo Nordisk A/SINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT01744691 | A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion | completed | Phase 2 | 145 | Pharmacyclics LLC.INDUSTRY | 9 | Feb 27, 2017 | clinicaltrials |
| NCT00880269 | Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 23, 2017 | clinicaltrials |
| NCT01019174 | Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma(MM_LEN_DEX_CY) | completed | Phase 1 / Phase 2 | 40 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01320111 | Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment(PASO) | completed | Phase 2 | 59 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT01220271 | A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 / Phase 2 | 75 | Eli Lilly and CompanyINDUSTRY | 3 | Feb 16, 2017 | clinicaltrials |
| NCT00815945 | Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors | completed | Phase 2 | 41 | AGO Study GroupOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT01471782 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 93 | Amgen Research (Munich) GmbHINDUSTRY | 7 | Feb 8, 2017 | clinicaltrials |
| NCT00976989 | A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer | completed | Phase 2 | 225 | Hoffmann-La RocheINDUSTRY | 20 | Feb 6, 2017 | clinicaltrials |
| NCT00080262 | Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) | completed | Phase 2 | 125 | R-PharmINDUSTRY | 10 | Jan 30, 2017 | clinicaltrials |
| NCT00813943 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status(CORE) | completed | Phase 2 | 265 | EMD SeronoINDUSTRY | 2 | Jan 30, 2017 | clinicaltrials |
| NCT01186991 | Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer | completed | Phase 2 | 185 | Genentech, Inc.INDUSTRY | 6 | Jan 20, 2017 | clinicaltrials |
| NCT00842712 | Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)(CERTO) | completed | Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 8 | Jan 13, 2017 | clinicaltrials |
| NCT01820364 | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma(LOGIC) | terminated | Phase 2 | 15 | Array BioPharmaINDUSTRY | 6 | Jan 9, 2017 | clinicaltrials |
| NCT01741792 | Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 25 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Jan 6, 2017 | clinicaltrials |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients(HERMIONE) | terminated | Phase 2 / Phase 3 | 113 | Merrimack PharmaceuticalsINDUSTRY | 9 | Jan 6, 2017 | clinicaltrials |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer(TIME) | terminated | Phase 2 / Phase 3 | 222 | TransgeneINDUSTRY | 10 | Jan 5, 2017 | clinicaltrials |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity | terminated | Phase 1 / Phase 2 | 3 | Innate PharmaINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT02107378 | Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma | terminated | Phase 2 | 22 | SOTIO a.s.INDUSTRY | 3 | Nov 30, 2016 | clinicaltrials |
| NCT00874848 | Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | HiberCell, Inc.INDUSTRY | 2 | Nov 29, 2016 | clinicaltrials |
| NCT01565083 | A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer(VELVET) | completed | Phase 2 | 213 | Hoffmann-La RocheINDUSTRY | 7 | Nov 22, 2016 | clinicaltrials |
| NCT02465814 | Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids(ASTEROID 2) | completed | Phase 2 | 120 | BayerINDUSTRY | 16 | Nov 22, 2016 | clinicaltrials |
| NCT00427999 | Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer(INV342) | completed | Phase 2 | 67 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 21, 2016 | clinicaltrials |
| NCT00171808 | Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer(deFEND) | completed | Phase 2 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials